View Financial HealthActavia Life Sciences 配当と自社株買い配当金 基準チェック /06Actavia Life Sciences配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 16Actavia Life Sciences, Inc. announced delayed 10-Q filingOn 08/15/2024, Actavia Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Actavia Life Sciences, Inc. announced delayed 10-Q filingOn 05/15/2024, Actavia Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 15Actavia Life Sciences, Inc. announced delayed 10-Q filingOn 02/14/2024, Actavia Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 30Actavia Life Sciences, Inc. announced delayed annual 10-K filingOn 12/29/2023, Actavia Life Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 29Rasna Therapeutics, Inc. announced delayed annual 10-K filingOn 12/28/2022, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 16Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2022, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2022, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 15Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 02/14/2022, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 30Rasna Therapeutics, Inc. announced delayed annual 10-K filingOn 12/29/2021, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • May 18Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 18Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 02/16/2021, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 01Rasna Therapeutics, Inc. announced delayed annual 10-K filingOn 12/30/2020, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 30Rasna Therapeutics, Inc. Announces Board ChangesOn December 21, 2020, Dr. Kunwar Shailubhai resigned as a director of Rasna Therapeutics, Inc. (the "Company") for personal reasons and on December 23, 2020, the Board of the Company appointed Gary S. Jacob as a director of the Company.お知らせ • Oct 16Rasna Therapeutics, Inc Announces Board ChangesRasna Therapeutics, Inc. announced that Willy Simon has been appointed as the Chairman of Rasna Therapeutics, replacing Alessandro Padova, who resigned for personal reasons. Mr. Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. He was previously chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc. Willy Simon has been the chairman of Bever Holdings, since 2006 and Chairman of Ducat Maritime since 2015. He also serves as the Executive Chairman of OKYO Pharma Ltd. and is a board member of Tiziana Life Sciences plc.お知らせ • Aug 15Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2020, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.決済の安定と成長配当データの取得安定した配当: RASPの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: RASPの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Actavia Life Sciences 配当利回り対市場RASP 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (RASP)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Biotechs)2.4%アナリスト予想 (RASP) (最長3年)n/a注目すべき配当: RASPは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: RASPは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: RASPの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: RASPが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/25 03:24終値2025/12/26 00:00収益2024/03/31年間収益2023/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Actavia Life Sciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 16Actavia Life Sciences, Inc. announced delayed 10-Q filingOn 08/15/2024, Actavia Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Actavia Life Sciences, Inc. announced delayed 10-Q filingOn 05/15/2024, Actavia Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 15Actavia Life Sciences, Inc. announced delayed 10-Q filingOn 02/14/2024, Actavia Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 30Actavia Life Sciences, Inc. announced delayed annual 10-K filingOn 12/29/2023, Actavia Life Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 29Rasna Therapeutics, Inc. announced delayed annual 10-K filingOn 12/28/2022, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 16Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 08/15/2022, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2022, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 15Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 02/14/2022, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 30Rasna Therapeutics, Inc. announced delayed annual 10-K filingOn 12/29/2021, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • May 18Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 05/17/2021, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 18Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 02/16/2021, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 01Rasna Therapeutics, Inc. announced delayed annual 10-K filingOn 12/30/2020, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 30Rasna Therapeutics, Inc. Announces Board ChangesOn December 21, 2020, Dr. Kunwar Shailubhai resigned as a director of Rasna Therapeutics, Inc. (the "Company") for personal reasons and on December 23, 2020, the Board of the Company appointed Gary S. Jacob as a director of the Company.
お知らせ • Oct 16Rasna Therapeutics, Inc Announces Board ChangesRasna Therapeutics, Inc. announced that Willy Simon has been appointed as the Chairman of Rasna Therapeutics, replacing Alessandro Padova, who resigned for personal reasons. Mr. Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. He was previously chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc. Willy Simon has been the chairman of Bever Holdings, since 2006 and Chairman of Ducat Maritime since 2015. He also serves as the Executive Chairman of OKYO Pharma Ltd. and is a board member of Tiziana Life Sciences plc.
お知らせ • Aug 15Rasna Therapeutics, Inc. announced delayed 10-Q filingOn 08/14/2020, Rasna Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.